findmyKOL
Clinical trialNCT02506153Active, not recruitingPhase 3Interventional

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

SponsorNational Cancer Institute (NCI)Enrollment1,301Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Cutaneous MelanomaMetastatic Mucosal MelanomaMetastatic Non-Cutaneous MelanomaNon-Cutaneous Melanoma+3 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Immunotherapy with monoclonal antibodies, such as ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether pembrolizumab is more effective than the current standard of care in treating patients with melanoma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

576 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Bcca-Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • the Vitalite Health Network - Dr Leon Richard Oncology Centre

    Moncton, New Brunswick, Canada

  • Royal Victoria Regional Health Centre

    Barrie, Ontario, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada

  • Waterloo Regional Health Network

    Kitchener, Ontario, Canada

  • London Regional Cancer Program

    London, Ontario, Canada

  • Trillium Health Partners - Credit Valley Hospital

    Mississauga, Ontario, Canada

  • Lakeridge Health Oshawa

    Oshawa, Ontario, Canada

  • Ottawa Hospital and Cancer Center-General Campus

    Ottawa, Ontario, Canada

  • Algoma District Cancer Program Sault Area Hospital

    Sault Ste. Marie, Ontario, Canada

  • Thunder Bay Regional Health Science Centre

    Thunder Bay, Ontario, Canada

  • Odette Cancer Centre- Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • University Health Network-Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Windsor Regional Cancer Centre

    Windsor, Ontario, Canada

  • Hopital de la Cite-de-la-Sante

    Laval, Quebec, Canada

  • the Research Institute of the Mcgill University Health Centre (muhc)

    Montreal, Quebec, Canada

  • Chu de Quebec-L'Hotel-Dieu de Quebec (hdq)

    Québec, Quebec, Canada

  • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont

    Sherbrooke, Quebec, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada

Ireland
  • Saint Vincent'S University Hospital

    Dublin, Co Dublin, Ireland

  • University College Hospital Galway

    Galway, Co Galway, Ireland

  • University Hospital Waterford

    Waterford, Co Waterford, Ireland

United States
  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, United States

  • Cancer Center at Saint Joseph'S

    Phoenix, Arizona, United States

  • Virginia G Piper Cancer Care-del Camino

    Scottsdale, Arizona, United States

  • Banner University Medical Center - Tucson

    Tucson, Arizona, United States

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona, United States

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, United States

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas, United States

  • Kaiser Permanente-Anaheim

    Anaheim, California, United States

  • Sutter Auburn Faith Hospital

    Auburn, California, United States

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California, United States

  • Kaiser Permanente-Bellflower

    Bellflower, California, United States

  • Uc Irvine Health Cancer Center-Newport

    Costa Mesa, California, United States

  • City of Hope Comprehensive Cancer Center

    Duarte, California, United States

  • Kaiser Permanente-Fontana

    Fontana, California, United States

  • Kaiser Permanente-Fremont

    Fremont, California, United States

  • Palo Alto Medical Foundation-Fremont

    Fremont, California, United States

536 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ipilimumab →Pembrolizumab →Interferon alfa-2b
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Nov 2015
Primary completion
15 Sept 2023
Completion
23 Jan 2027
Last update posted
14 Aug 2026
Registered enrollment
1,301
Registry id
NCT02506153
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.